Famicord Ag
- Company typePublic
- Founded2024
- HeadquartersLeipzig, Germany
- Headcount—
- GTM typeB2B and B2C
- OfferingServices
Famicord Ag firmographics
Firmographics- Name
- Famicord Ag
- Legal name
- FamiCord AG
- Website
- https://famicord.com
- Company type
- Public
- Founded year
- 2024
- Operating status
- Operating
- Ownership category
- akta.pro rank
Famicord Ag industry classification
Industry- Product category
- Stem Cell Banking
- NAICS
- Blood and Organ Banks (621991), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)
- akta.pro secondary industries
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)
Keywords
Where Famicord Ag is headquartered
LocationHeadquarters
- HQ city
- Leipzig
- HQ country
- Germany
- HQ region
- Europe
Offices4 records
Markets served
Famicord Ag business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Family Stem Cell Banking Subscriptions: Ongoing subscription-based services for stem cell collection, processing, and long-term storage for families. Revenue generated through annual storage fees and initial processing fees.
- CDMO Services for Biotech/Pharma: Contract manufacturing and development services for biotechnology companies and clinics, including process development, validation, cGMP manufacturing, and quality control for cell therapy products and ATMPs.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Famicord Ag product offering
Product offeringCore offering
FamiCord AG is the parent of the FamiCord Group, Europe's leading stem cell bank. Its core offerings are (1) family stem cell banking — collection, processing, testing, and long-term cryogenic storage of umbilical cord blood, cord tissue, and placenta tissue for expectant families — and (2) CDMO services for biotechnology companies and clinics, providing process development, tech transfer, cGMP manufacturing, analytics, cell/tissue sourcing, and global logistics for cell therapy ATMPs (Advanced Therapy Medicinal Products). The group operates cGMP-compliant manufacturing facilities in Warsaw (Poland), Cantanhede (Portugal), Leipzig (Germany), and Rostock (Germany), supporting autologous and allogeneic cell therapy programs from preclinical through clinical phases.
Product overview
FamiCord operates as a pan-European stem cell bank offering family banking services for umbilical cord blood and tissue preservation, alongside a CDMO (Contract Development and Manufacturing Organization) segment providing cell therapy development and manufacturing services to biotech companies and clinics. The company operates two cGMP-compliant manufacturing facilities in Warsaw (Poland) and Cantanhede (Portugal). Key offerings include Stem Cells Banking (family banking), CDMO Services, Compassionate Use Program/Expanded Access Programme for ASD and cerebral palsy treatments, and Stem Cell Applications for transplants. FamiCord is the first and leading European stem cell bank with over 1,000,000 stored cord blood units and partnerships with over 1,500 clinics across Europe.
Differentiator
Problem solved
Functional benefit
Brands
- VitaPlus: Stem cell banking contract variant offered by FamiCord
- VitaPlusCord
Products and services
- Stem Cells Banking Family banking service covering the collection, processing, testing, and long-term cryogenic storage of umbilical cord blood, umbilical cord tissue, and placenta tissue from newborns, intended to preserve perinatal cells for potential future medical treatments of the child or family members.
- CDMO Services for Cell Therapy ATMPs Contract Development and Manufacturing Organization services for biotech companies and clinics developing cell therapy Advanced Therapy Medicinal Products (ATMPs). Scope includes process development and optimization, technology transfer, cGMP manufacturing, cell and tissue sourcing, analytics, and global logistics, supporting autologous and allogeneic programs from preclinical through clinical phases.
- Compassionate Use Program / Expanded Access Programme Programme enabling families to access stem cell treatments for autism spectrum disorders and cerebral palsy using the child's own stored umbilical cord blood, leveraging FamiCord's position as the only private cord blood bank in Europe providing cells for innovative experimental therapies and clinical research.
- Stem Cell Applications (Transplants and Infusions) Therapeutic application services providing stem cell transplants and infusions to patients, using FamiCord-stored cord blood and tissue. The application portfolio has supported over 8,000 patients treated and over 260 cord blood transplantations or infusions enabled.
Quantifiable outcome
- Stored over 1,000,000 cord blood units and other biological materials
- +2 more outcomes
Companies that use Famicord Ag
Customer profileNamed customers5 records
Segments2 records
Ideal customer profiles2 records
Famicord Ag technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Famicord Ag partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- ArTheccoreArThec is a new CDMO customer acquired by FamiCord AG in June 2026, representing further expansion in the CDMO business segment.
- US Biotechnology CompanycoreAllogeneic cell therapy partnership for muscular dystrophy treatment. FamiCord provides technology transfer into the manufacturing process and cGMP production/QC release. Ongoing partnership since 2021.
- German Biotechnology CompanyminorProcess development, validation, production and QC assessments for preclinical phase treatments of cartilage damage.
- Scandinavian Biotechnology CompanyminorProcess development, production and quality control for Phase II clinical trial for diabetes treatment.
- Polish University CliniccorePartnership since 2017 for manufacturing and quality controls for autologous ATMPs for Phase I/II clinical studies for dermatological applications.
- 1,500+ Clinics across Europe, Asia and AfricacoreExtensive network of cooperating clinics that refer families and/or process samples through FamiCord facilities.
- Academic InstitutionsminorPartnerships with academic institutions to contribute to advancements in regenerative medicine and biotechnology.
Scale indicators5 records
Recent moves1 record
Expansion highlights6 records
Famicord Ag competitors and assessment
Company assessmentBroad incumbents
- Lonza Group: Global contract development and manufacturing organization (CDMO) with significant cell and gene therapy manufacturing capacity. Comparable as a much larger incumbent serving FamiCord's same biotech CDMO customers.
- Charles River Laboratories: Global CRO/CDMO providing cell and gene therapy manufacturing and testing services. Comparable as a broad incumbent offering overlapping capabilities in cell therapy process development and GMP release.
- Catalent: Major global CDMO with biologics and cell therapy capabilities. Comparable as a large incumbent competing for cell therapy ATMP process development, tech transfer and GMP manufacturing work that FamiCord's CDMO segment targets.
Emerging players
- BioLife Solutions: Supplier of cryopreservation and biopreservation tools for cell and gene therapies. Comparable as an enabler/adjacent player whose products are used in the same cold-chain and cryogenic storage workflows that FamiCord runs.
- Caladrius Biosciences (PCT Cell Therapy Services): Cell therapy CDMO with PCT heritage offering cGMP manufacturing services. Comparable as an emerging peer in cell therapy contract manufacturing, a smaller and more focused alternative to FamiCord's CDMO offering.
Direct peers
- Cells4Life: UK-based private cord blood bank offering whole-blood and tissue storage. Directly comparable on the family banking subscription model and is a relevant UK/European private-bank competitor.
- Cord Blood Registry (CBR): One of the largest private family cord blood banks in the US, owned by CooperSurgical. Directly comparable to FamiCord on core DTC cord blood collection, processing and long-term storage service.
- Cryo-Cell International: US-listed private cord blood banking company offering family cord blood and menstrual cell storage. Directly comparable to FamiCord's family banking subscription business and recurring storage revenue model.
- ViaCord (Revvity): Family cord blood and cord tissue banking service operating under Revvity/PerkinElmer. Directly comparable on family banking value proposition, scientific positioning and recurring storage model.
Regional players
- Crioestaminal: Portuguese private cord blood bank that is part of the FamiCord family (Cantanhede site). Relevant as a regional European private-bank peer operating under FamiCord's own platform and network.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Famicord Ag social profiles
Digital presenceFamicord Ag compliance and trust
Trust signalCompliance7 records
Famicord Ag financial estimates
Financial estimateRevenue estimate
Valuation estimate
Famicord Ag leadership team
Management profileNumber of profiles
Profiles5 records
Famicord Ag subsidiaries and ownership
Company hierarchySubsidiaries6 records
Famicord Ag funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Famicord Ag M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Famicord Ag
What does Famicord Ag do?
FamiCord AG is the parent of the FamiCord Group, Europe's leading stem cell bank. Its core offerings are (1) family stem cell banking — collection, processing, testing, and long-term cryogenic storage of umbilical cord blood, cord tissue, and placenta tissue for expectant families — and (2) CDMO services for biotechnology companies and clinics, providing process development, tech transfer, cGMP manufacturing, analytics, cell/tissue sourcing, and global logistics for cell therapy ATMPs (Advanced Therapy Medicinal Products). The group operates cGMP-compliant manufacturing facilities in Warsaw (Poland), Cantanhede (Portugal), Leipzig (Germany), and Rostock (Germany), supporting autologous and allogeneic cell therapy programs from preclinical through clinical phases.
Is Famicord Ag a public or private company?
Famicord Ag is a public company. It is classified as public and is currently operating.
When was Famicord Ag founded?
Famicord Ag was founded in 2024.
Where is Famicord Ag based?
Famicord Ag is headquartered in Leipzig, Germany, in the Europe region.
How does Famicord Ag make money?
Two revenue lines are on record. Family Stem Cell Banking Subscriptions are the primary driver. The others are CDMO Services for Biotech/Pharma.
Who are Famicord Ag's main competitors?
Broad incumbents on record are Lonza Group, Charles River Laboratories and Catalent. Emerging players are BioLife Solutions and Caladrius Biosciences (PCT Cell Therapy Services). Direct peers are Cells4Life, Cord Blood Registry (CBR), Cryo-Cell International and ViaCord (Revvity). Crioestaminal is listed as a regional player.
Does Famicord Ag have an API?
No public API is recorded for Famicord Ag.
What industry is Famicord Ag in?
Famicord Ag's product category is Stem Cell Banking. Its primary akta.pro industry code is HLAAAKAC, Cell Therapy Manufacturing Services (GMP, autologous/allogeneic), with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 621991 and its SIC code is 2836.